Trial designs and results supporting treatment de-escalation and escalation

Breast. 2017 Aug:34 Suppl 1:S10-S12. doi: 10.1016/j.breast.2017.06.020. Epub 2017 Jun 30.

Abstract

Trials for escalation and de-escalation of treatment aim to improve patient care, but from different sides of the same coin with respect to disease control and burdens of treatment. De-escalation of therapy is inherently a non-inferiority question. A design with random assignment to standard of care versus de-escalated therapy is typically implemented but ordinarily will require a large sample size. Some research questions of treatment de-escalation might be asked in select patient populations using single-arm designs. Trials of therapy escalation may better inform the care of individual patients by posing a clinically-oriented research question in an enriched patient population, or by planning analyses that exploit the heterogeneity of a broadly-defined enrolled population.

Keywords: Adjuvant therapy; Clinical trials; Non-inferiority.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / surgery
  • Chemotherapy, Adjuvant / methods
  • Clinical Trials as Topic*
  • Female
  • Humans
  • Research Design*

Substances

  • Antineoplastic Agents